nebicapone: Clinical Trials

12 completed. 10 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	10	Completed 10
Phase 2	2	Completed 2

Follow nebicapone: new trials by email Literature Review of nebicapone trials Research Report on nebicapone

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon Comtan®, Nebicapone, Levodopa/DDCI - Parkinson Disease	Phase 2	Completed	Bial - Portela C S.A.	254	2006-09-26	2017-04-06
Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin BIA 3-202, warfarin - Healthy	Phase 1	Completed	Bial - Portela C S.A.	16	2006-09-01	2017-08-24
Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg Placebo, BIA 6-512, Madopar® 250 - Parkinson Disease	Phase 1	Completed	Bial - Portela C S.A.	38	2006-07-17	2017-03-31
Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites BIA 3-202 (200 mg) - Parkinson's Disease	Phase 1	Completed	Bial - Portela C S.A.	4	2006-01-01	2016-05-13
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa BIA 3-202, Placebo, Sinemet® - Parkinson's Disease	Phase 1	Completed	Bial - Portela C S.A.	16	2005-09-01	2016-05-19
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide BIA 3-202, Placebo, levodopa 100 mg / benserazide 25 mg - Parkinson's Disease (PD)	Phase 1	Completed	Bial - Portela C S.A.	17	2005-09-01	2016-06-14
Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients Placebo, BIA 3-202, Comtan® - Parkinson's Disease (PD)	Phase 2	Completed	Bial - Portela C S.A.	19	2005-03-01	2016-07-15
Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202 Nebicapone, Placebo - Parkinson's Disease	Phase 1	Completed	Bial - Portela C S.A.	22	2001-09-01	2016-05-13
Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg) BIA 3-202, Placebo, Sinemet 25/100 - Parkinson's Disease	Phase 1	Completed	Bial - Portela C S.A.	19	2001-04-01	2016-05-05
Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg) BIA 3-202, Placebo, Madopar® 125 - Parkinson's Disease	Phase 1	Completed	Bial - Portela C S.A.	18	2001-04-01	2016-05-05
Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202 BIA 3-202, Placebo - Parkinson's Disease	Phase 1	Completed	Bial - Portela C S.A.	33	2000-09-01	2016-05-05
Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202 BIA 3-202, Placebo - Parkinson's Disease	Phase 1	Completed	Bial - Portela C S.A.	71	2000-04-01	2016-05-16

Conditions studied

Parkinson Disease (11)

Sponsors

Bial - Portela C S.A. (12)

Countries

Portugal (7)  ·  United Kingdom (2)  ·  Switzerland (1)